reverses diabetes type 2

🔥+ reverses diabetes type 2 08 Aug 2020 White Papers · Case Studies · ICD-10 · GPCI · Specialties. We use cookies on our website to give you the most relevant experience by remembering your ...

reverses diabetes type 2 The American Heart Association explains Diabetes, types 1 diabetes and type 2 diabetes, prediabetes, insulin resistance and how diabetes develops.

best cbd oil for type 2 diabetes
Advertisement
 
 

AFP Journal Club

The Story Behind for 1 last update 08 Aug 2020 the StudyThe Story Behind the Study

 

MARK A. GRABER, MD, University of Iowa Carver College of Medicine, Iowa City, Iowa

ANDREA DARBY-STEWART, MD, Mayo Clinic Family Medicine Residency Program, Scottsdale, Arizona

reverses diabetes type 2 pumps system (👍 blood test) | reverses diabetes type 2 symptoms mayo clinichow to reverses diabetes type 2 for ROBERT DACHS, MD, FAAFP, St. Clare''s Article

Kahn SE, Haffner SM, Heise MA, et al., for the 1 last update 08 Aug 2020 the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy [published correction appears in N Engl J Med. 2007;356(13):1387–1388]. N Engl J Med. 2006;355(23):2427–2443.Kahn SE, Haffner SM, Heise MA, et al., for the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy [published correction appears in N Engl J Med. 2007;356(13):1387–1388]. N Engl J Med. 2006;355(23):2427–2443.

Which controls type 2 diabetes best at five years: rosiglitazone, metformin, or glyburide?

the 1 last update 08 Aug 2020 MarkMark: For the estimated 20 million Americans with type 2 diabetes, this is a very important question. This article is an excellent demonstration of why reading just the abstract could lead you to the wrong conclusion.

What does this article say?

Mark: This study randomized 4,360 patients to monotherapy with rosiglitazone (Avandia), metformin (Glucophage), or glyburide (Micronase). The end point was fasting blood glucose over 180 mg per dL. The authors concluded that, at five years, only 15 percent of patients taking rosiglitazone failed mono-therapy versus 21 percent of those taking metformin and 34 percent taking glyburide. Although the abstract trumpets rosiglitazone as “the winner,” this is exactly the wrong conclusion to draw from this study.

Should we believe this study?

Mark: How did the authors come to the incorrect conclusion? First, fasting blood glucose was the wrong end point to measure. This is a surrogate marker of disease that does not correlate with clinical outcomes. Using such surrogate markers as end points is known as “DOE” or “disease-oriented evidence.” What we care about are patient out-comes, such as adverse cardiovascular events; these are known as “POEMs” or “patient-oriented evidence that matters.” Fasting blood glucose is a surrogate marker that is, perhaps, just as dependent on the half-life of the drug and when the drug was administered as anything else.

What about the more accepted gold standard A1C values (itself a DOE)? There was a negligible difference of 0.13 percent favoring the rosiglitazone group over the metformin group. This miniscule difference is clinically meaningless; it takes an increase of at least 1 percent in A1C level to barely increase the relative risk of a cardiovascular event to 1.18 (95% CI, 1.1 to 1.26).1

reverses diabetes type 2 is caused by (⭐️ nice) | reverses diabetes type 2 riskhow to reverses diabetes type 2 for And what did the study show about the clinical end points that we are really interested in, such as cardiovascular events? Patients on rosiglitazone had more CHF and a greater number of cardiovascular events than those on metformin or glyburide. These are the end points that matter.

Bob: Also, there was an average weight gain of 10.6 lb (4.8 kg) with rosiglitazone and 3.5 lb (1.6 kg) with glyburide, which is not something we need in patients with type 2 diabetes. Metformin resulted in a net weight loss of 6.4 lb (2.9 kg) over five years.

Mark: What disturbs me most is that the conclusion in the abstract is different from the conclusion in the body of the paper. What the authors conclude in the paper is that the “findings confirm the value of metformin as an initial treatment for type 2 diabetes.” This is entirely different than what they concluded in the abstract.

reverses diabetes type 2 young age (🔴 rash) | reverses diabetes type 2 and urinehow to reverses diabetes type 2 for Andrea: This disconnect between what is reported in the body of a paper and what is promoted in the abstract is not a new problem. In a review of first-tier journals, the data in the abstract differed from the data in the paper up to 68 percent of the time.2 This tells you that if you just read the abstract, you may be misled.

Additionally, the common use of surrogate outcomes is problematic. For example, we don''t help your heart, oh, and by the way, there is a small chance it may make you worse.” Any takers?

Andrea: I agree. Start with metformin. This study should the 1 last update 08 Aug 2020 also serve as a warning that abstracts may not reflect the true results of a study, even in journals like the New England Journal of Medicine. You should evaluate the study yourself before you change your clinical practice (or find a group of medical nerds like us to do it for you).Andrea: I agree. Start with metformin. This study should also serve as a warning that abstracts may not reflect the true results of a study, even in journals like the New England Journal of Medicine. You should evaluate the study yourself before you change your clinical practice (or find a group of medical nerds like us to do it for you).

Main Points

  • Glitazones are associated with fluid retention, increased CHF rates, and, possibly, increased rates of cardiovascular events compared with sulfonylureas and for 1 last update 08 Aug 2020 metformin.Glitazones are associated with fluid retention, increased CHF rates, and, possibly, increased rates of cardiovascular events compared with sulfonylureas and metformin.

  • The FDA and the Canadian government have issued warnings about CHF and cardiovascular events with rosiglitazone.

  • Metformin should be the first-line drug for managing type 2 diabetes. Insulin and sulfonylureas should be second line, and glitazones should be reserved for third line.

  • Metformin is the only drug for type 2 diabetes that does not cause weight gain, which is an important advantage.

reverses diabetes type 2 teenager (🔴 and insulin) | reverses diabetes type 2 pathophysiologyhow to reverses diabetes type 2 for EBM Points

  • The data and conclusion in the abstract of an article may not be the same as the data in the paper. If you read only the abstract, you may be misled.

  • A lot of studies use surrogate markers as outcomes (e.g., fasting or postprandial blood glucose, FEV1). These are DOEs. What we care about are POEMs (e.g., stroke rates, MI rates, quality of life).

  • Something can be statistically significant but clinically meaningless (for example, A1C difference of 0.08 percent).

Read the full article.

  • Get immediate access, anytime, anywhere.
  • Choose a single article, issue, or full-access subscription.
  • Earn up to 6 CME credits per issue.
Already a member/subscriber?

Log in >>

Already a member or subscriber? Log in

 

Best Value!

Get Full Access

From $140

  • Includes:
  • Immediate, unlimited access to all AFP content
  • More than 130 CME credits per year
  • Access to the AFP app
  • Print delivery option

 

Access This Issue

$39.95

 
  • Includes:
  • Immediate access to this issue
  •   CME credits in this issue

 
 
To see the full article, log in or purchase access.

Address correspondence to Mark A. Graber, MD, at [email protected] Reprints are not available from the authors.

Author disclosure: Nothing to disclose.

reverses diabetes type 2 graph (👍 fruits to eat) | reverses diabetes type 2 testhow to reverses diabetes type 2 for References

show all references

1. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141(6):421–431....

2. Pitkin RM, Branagan MA, Burmeister LF. Accuracy of data in abstracts of published for 1 last update 08 Aug 2020 research articles. JAMA. 1999;281(12):1110–1111.2. Pitkin RM, Branagan MA, Burmeister LF. Accuracy of data in abstracts of published research articles. JAMA. 1999;281(12):1110–1111.

reverses diabetes type 2 dinner recipes (🔥 vitamin d) | reverses diabetes type 2 risk factorshow to reverses diabetes type 2 for 3. Verma S, Strauss M. Angiotensin receptor blockers and myocardial infarction. BMJ. 2004;329(7477)1248–1249.

4. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366(9496)1545–1553.

the 1 last update 08 Aug 2020 5. 5. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes [published correction appears in N Engl J Med. 2007;357(1):100]. N Engl J Med. 2007;356(24):2457–2471.

For more information on EBM terms, see the EBM Toolkit at https://www.aafp.org/afp/ebmtoolkit.

 

 

Copyright © 2008 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact [email protected] for copyright questions and/or permission requests.

  • SHARE

reverses diabetes type 2 weight gain (🔥 mellitus nature) | reverses diabetes type 2 ketohow to reverses diabetes type 2 for Want to use this article elsewhere? Get Permissions

Advertisement

More in AFP


reverses diabetes type 2 mellitus 10 code (⭐️ education) | reverses diabetes type 2 veganhow to reverses diabetes type 2 for Editor''t miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article


Continue reading from January 1, 2008

Previous: Academy the 1 last update 08 Aug 2020 Introduces New Organizational Seal; Immunization Schedules in this Issue Previous: Academy Introduces New Organizational Seal; Immunization Schedules in this Issue

Next: AAFP News Now: AFP Edition

View the full table of contents >>

Home / Journals the 1 last update 08 Aug 2020 // afp / Vol. 77/No. 1(January 1, 2008) / AFP Journal Club: Choosing First-Line Therapy for Management of Type 2 Diabetes